Study Looks At Clinical Trial That Tested Estrogen-Plus-Progestin Combination
October 29, 2011
Healthcare Prof:
4 (1 votes)
Women who developed new-onset breast tenderness right after beginning estrogen plus progestin hormone replacement therapy were at substantially higher risk for creating breast cancer than girls on the combination therapy who didn’t experience such tenderness, based on a new UCLA study.
The investigation, published inside the Oct. 12 issue of the Archives of Internal Medicine, is based on information from more than 16,000 participants within the Women’s Well being Initiative estrogen-plus- progestin clinical trial. This trial was abruptly halted in July 2002 when researchers identified that healthy menopausal females on the combination therapy had an elevated danger for invasive breast cancer.
Researchers do not know why breast tenderness indicates increased cancer danger amongst girls on the combination therapy, said the new study’s lead researcher, Dr. Carolyn J. Crandall, a clinical professor of general internal medicine and wellness services investigation in the David Geffen School of Medicine at UCLA.
“Is it because the hormone therapy is causing breast-tissue cells to multiply more rapidly, which causes breast tenderness and in the exact same time indicates increased cancer danger? We have to figure out what makes certain ladies a lot more susceptible to developing breast tenderness in the course of hormone therapy than other girls,” Crandall said.
This study compared the every day use of oral conjugated equine estrogens (0.625 mg) plus medroxyprogesterone acetate (2.5 mg), or CEE+MPA, using the everyday use of a placebo pill.
Of the participants within the trial, 8,506 took estrogen plus progestin and 8,102 were given placebos. Participants underwent mammography and clinical breast exams at the start of the trial and annually thereafter. Self-reported breast tenderness was assessed at the beginning of the trial and 1 year later, and invasive breast cancer over the next five.6 years was confirmed by medical record review.
Women on the combination therapy who did not have breast tenderness at the trial’s inception had been identified to have a threefold greater risk of developing tenderness in the one-year mark, compared with participants who had been assigned placebos (36.1 percent vs. 11.8 percent). Amongst the females who did report breast tenderness in the beginning, the danger at one-year was about 1.26 occasions that of their counterparts on placebos.
Of the ladies who reported new-onset breast tenderness, 76.3 percent had been on the combination therapy.
Women within the combination therapy group who did not have breast tenderness at the outset but experienced new-onset tenderness in the initial annual follow-up had a 48 percent greater danger of invasive breast cancer than their counterparts on combination therapy who didn’t have breast tenderness at the first-year follow-up.
“To our knowledge, no prior published studies have addressed no matter whether there’s an association between CEE+MPA-induced new-onset breast tenderness and breast cancer threat,” Crandall said.
The study does have limitations. The information the researchers utilized assessed breast tenderness only annually and thus could have underestimated it. Also, the rates of girls discontinuing the combination therapy and switching from placebos to active therapy were relatively high, although the researchers believe this could have decreased, rather than increased, the observed association among new-onset tenderness and cancer risk. And the results do not apply to other sorts of estrogen or progestin therapy.
Study co-authors had been Rowan Chlebowski of UCLA; Aaron K. Aragaki, Anne McTiernan and Garnet Anderson of the Fred Hutchinson Cancer Investigation Center in Seattle; Susan L. Hendrix of Wayne State University-Hutzel Women’s Hospital in Detroit; Barbara B. Cochrane of the University of Washington; and Lewis H. Kuller and Jane A. Cauley of the University of Pittsburgh.
Grants from the National Institute on Aging as well as the Tarlow-Eisner-Moss Research Endowment of the Iris Cantor-UCLA Women’s Health Center funded Crandall’s investigation. Funding for the Women’s Well being Initiative comes by means of the National Heart, Lung and Blood Institute of the National Institutes of Wellness.
Source:
Enrique Rivero
University of California – Los Angeles
Filed under: French Village